March 24, 2025 - 19:48
Private equity firm Jeito Capital has announced its role as a co-leader in an oversubscribed Series A financing round, raising €77.7 million (approximately USD 84.8 million) for Augustine Therapeutics. This significant funding will primarily support the advancement of AGT-100216, Augustine's leading therapeutic candidate aimed at treating Charcot-Marie-Tooth disease, a genetic disorder affecting peripheral nerves.
In addition to bolstering the development of AGT-100216, the financing will also facilitate the expansion of Augustine's pipeline into other critical areas, including cardio-metabolic and neurodegenerative diseases. This strategic investment underscores Jeito Capital's commitment to fostering innovation in the biotechnology sector and highlights the growing interest in therapies that address complex neurological conditions.
The successful completion of this funding round positions Augustine Therapeutics to accelerate its research and development efforts, ultimately aiming to bring transformative treatments to patients in need.
